EA201591773A1 - Макроциклические ингибиторы rip2-киназы - Google Patents

Макроциклические ингибиторы rip2-киназы

Info

Publication number
EA201591773A1
EA201591773A1 EA201591773A EA201591773A EA201591773A1 EA 201591773 A1 EA201591773 A1 EA 201591773A1 EA 201591773 A EA201591773 A EA 201591773A EA 201591773 A EA201591773 A EA 201591773A EA 201591773 A1 EA201591773 A1 EA 201591773A1
Authority
EA
Eurasian Patent Office
Prior art keywords
rip2
kinase
inhibitors
macro cyclic
cyclic inhibitors
Prior art date
Application number
EA201591773A
Other languages
English (en)
Inventor
Петра Марселла Франсуаза Блом
Ян Мари Сирил Йозеф Хофлак
Паскаль Андре Рене Бендериттер
Original Assignee
Онкодизайн С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1304714.7A external-priority patent/GB201304714D0/en
Application filed by Онкодизайн С.А. filed Critical Онкодизайн С.А.
Publication of EA201591773A1 publication Critical patent/EA201591773A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Изобретение относится к макроциклическим соединениям и композициям, содержащим указанные соединения, действующие в качестве ингибиторов киназ, в частности в качестве ингибиторов RIP2 и/или ее мутантов, для применения в диагностике, предупреждении и/или лечении ассоциированных с RIР2-киназой заболеваний. Более того, в изобретении предложены способы применения указанных соединений, например, в качестве лекарственного или диагностического средства.
EA201591773A 2013-03-15 2014-03-14 Макроциклические ингибиторы rip2-киназы EA201591773A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1304714.7A GB201304714D0 (en) 2013-03-15 2013-03-15 Macrocyclic RIP2 Kinase inhibitors
EP2013066732 2013-03-15
PCT/EP2014/055139 WO2014140299A1 (en) 2013-03-15 2014-03-14 Macrocyclic rip2 kinase inhibitors

Publications (1)

Publication Number Publication Date
EA201591773A1 true EA201591773A1 (ru) 2016-01-29

Family

ID=50342296

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591773A EA201591773A1 (ru) 2013-03-15 2014-03-14 Макроциклические ингибиторы rip2-киназы

Country Status (13)

Country Link
US (1) US20160024114A1 (ru)
JP (1) JP2016510796A (ru)
KR (1) KR20150133765A (ru)
CN (1) CN105228625A (ru)
AU (1) AU2014230111A1 (ru)
BR (1) BR112015022982A2 (ru)
CA (1) CA2906257A1 (ru)
EA (1) EA201591773A1 (ru)
HK (1) HK1218263A1 (ru)
IL (1) IL241250A0 (ru)
MX (1) MX2015012526A (ru)
SG (1) SG11201507594YA (ru)
WO (1) WO2014140299A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016146651A1 (en) * 2015-03-16 2016-09-22 Oncodesign Sa Macrocyclic activin-like receptor kinase inhibitors
JP2019516715A (ja) 2016-05-19 2019-06-20 ユニバーシタット アントウェルペン Ｐａｒ関連疾患の予防および／または治療における使用のためのビス（アセトアミドフェニル）グアニジノフェニルエチルホスホネート
SG11201900163PA (en) * 2016-07-28 2019-02-27 Tp Therapeutics Inc Macrocycle kinase inhibitors
KR20180088113A (ko) * 2017-01-26 2018-08-03 한미약품 주식회사 이미다조피리다진 화합물
JP7092405B2 (ja) * 2018-04-16 2022-06-28 深▲チェン▼市塔吉瑞生物医薬有限公司 キナーゼ活性を阻害するためのジ（ヘテロ）アリール大環状化合物
JP2022505987A (ja) 2018-10-22 2022-01-14 エスカー セラピューティクス，インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
BR112022014925B1 (pt) * 2020-01-31 2023-12-19 Oncodesign Precision Medicine (OPM) Inibidores macrocíclicos de rip2-quinase, seus usos, e composição farmacêutica
CN117659043A (zh) * 2022-09-07 2024-03-08 苏州朗睿生物医药有限公司 一种大环咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ120999A0 (en) * 1999-06-25 1999-07-22 Industrial Automation Services Pty Ltd Vibration suppressing piston
JP2004089182A (ja) * 2002-06-24 2004-03-25 Takeda Chem Ind Ltd がんの予防・治療剤
TWI547494B (zh) * 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
UA113186C2 (xx) * 2011-09-30 2016-12-26 Макроциклічні інгібітори lrrk2 кінази
CN103930427B (zh) * 2011-09-30 2016-03-09 昂科迪塞恩股份有限公司 大环flt3激酶抑制剂
AU2014230125A1 (en) * 2013-03-15 2015-10-29 Oncodesign S.A. Macrocyclic salt-inducible kinase inhibitors
CA2904462A1 (en) * 2013-03-15 2014-09-18 Ipsen Pharma S.A.S Macrocyclic lrrk2 kinase inhibitors

Also Published As

Publication number Publication date
JP2016510796A (ja) 2016-04-11
US20160024114A1 (en) 2016-01-28
MX2015012526A (es) 2016-04-26
IL241250A0 (en) 2015-11-30
CA2906257A1 (en) 2014-09-18
BR112015022982A2 (pt) 2017-07-18
SG11201507594YA (en) 2015-10-29
KR20150133765A (ko) 2015-11-30
WO2014140299A1 (en) 2014-09-18
HK1218263A1 (zh) 2017-02-10
CN105228625A (zh) 2016-01-06
AU2014230111A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
EA201591773A1 (ru) Макроциклические ингибиторы rip2-киназы
EA201591698A1 (ru) Макроциклические ингибиторы киназы lrrk2
MX2015012528A (es) Inhibidores macrociclicos de cinasa inducibles por sal.
MX2019001125A (es) Inhibidores de cinasa macrociclica.
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
EA201690159A1 (ru) Способы и композиции для лечения рака
IN2015DN01156A (ru)
NZ751197A (en) Compounds and methods of treating infections
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201790273A1 (ru) Флагеллиновые композиции и их применение
BR112015017241A2 (pt) doadores de nitroxil com índice terapêutico melhorado
CL2015000615A1 (es) Compuestos derivados de 4-amino-quinolinas, inhibidores de rip2 cinasa; composicion farmaceutica que los comprende; uso para el tratamiento de enfermedades tales como enfermedad de crohn, colitis ulcerativa o sindrome de blau.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
TR201904514T4 (tr) Makrosiklik LRRK2 kinaz inhibitörleri.
EA201791363A1 (ru) Пиразолопиридинамины в качестве ингибиторов mknk1 и mknk2
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
EA201792341A1 (ru) Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap)
EA201501187A1 (ru) Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
EA201790609A1 (ru) Макроциклические ингибиторы rip2-киназы
EA201790973A1 (ru) A-антагонист в низкой дозировке для лечения adhd и болезни паркинсона
IN2015DN02109A (ru)